Bank of America’s IGC Pharma IGC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-1,808
Closed -$508 6267
2025
Q4
$508 Sell
1,808
-2,150
-54% -$766 ﹤0.01% 6556
2025
Q3
$1.65K Buy
3,958
+3,231
+444% +$1.23K ﹤0.01% 7424
2025
Q2
$223 Buy
727
+123
+20% +$37 ﹤0.01% 7823
2025
Q1
$172 Buy
604
+31
+5% +$10 ﹤0.01% 7723
2024
Q4
$193 Buy
573
+10
+2% +$4 ﹤0.01% 7593
2024
Q3
$240 Buy
563
+146
+35% +$59 ﹤0.01% 7527
2024
Q2
$181 Buy
+417
New +$207 ﹤0.01% 7575
2023
Q4
Sell
-250
Closed -$90 8098
2023
Q3
$90 Hold
250
﹤0.01% 7473
2023
Q2
$78 Buy
250
+230
+1,150% +$75 ﹤0.01% 7439
2023
Q1
$7 Buy
+20
New +$8 ﹤0.01% 7658
2022
Q1
Sell
-90,320
Closed -$88K 8481
2021
Q4
$88K Sell
90,320
-6,676
-7% -$8.96K ﹤0.01% 6937
2021
Q3
$144K Buy
96,996
+96,618
+25,560% +$156K ﹤0.01% 6512
2021
Q2
$1K Sell
378
-10,770
-97% -$16.4K ﹤0.01% 7615
2021
Q1
$20K Buy
+11,148
New +$20.3K ﹤0.01% 6885
2020
Q4
Sell
-225
Closed 7201
2020
Q3
$0 Buy
+225
New +$229 ﹤0.01% 7011
2019
Q3
Sell
-2,680
Closed -$4K 7349
2019
Q2
$4K Buy
+2,680
New +$3.79K ﹤0.01% 6869
2018
Q4
Sell
-500
Closed -$3K 7220
2018
Q3
$3K Buy
+500
New +$520 ﹤0.01% 6947
2015
Q3
Sell
-2,000
Closed -$1K 7293
2015
Q2
$1K Buy
+2,000
New +$880 ﹤0.01% 7126

Other funds holding IGC

Bank of America's IGC Position: Q1 2026 in Review

Bank of America sold out of IGC Pharma (IGC) in Q1 2026, closing a stake of 1,808 shares — an estimated $508 sold.

Bank of America first reported a position in IGC in Q2 2015 and held it in 18 quarters. The position peaked at $144K in Q3 2021. 35 funds tracked by Wall St. Rank hold IGC as of Q1 2026.

  • Bank of America reported no remaining IGC Pharma position as of Q1 2026 after selling out during the quarter.
  • Bank of America sold 1,808 IGC Pharma shares in Q1 2026, an estimated $508.
  • Bank of America first reported a position in IGC Pharma in Q2 2015 and held it in 18 quarters.
  • Bank of America's IGC Pharma position peaked at $144K in Q3 2021.
  • 35 funds tracked by Wall St. Rank held IGC Pharma as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.